Emerg Infect DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention18252127285730906-111610.3201/eid1309.061116DispatchIncrease in Clostridium difficile–related
Mortality Rates, United States, 1999–2004Clostridium
difficile–related Mortality RatesRedelingsMatthew D.*SorvilloFrank*†MascolaLaurene*Los Angeles County Department of Public Health, Los
Angeles, California, USAUniversity of California Los
Angeles–School of Public Health, Los Angeles, California, USAAddress for correspondence: Matthew D. Redelings, 313 N Figueroa
127, Los Angeles, CA 90012, USA; email: mredelings@dhs.co.la.ca.us9200713914171419
Reported mortality rates from Clostridium difficile disease in
the United States increased from 5.7 per million population in 1999 to 23.7 per
million in 2004. Increased rates may be due to emergence of a highly virulent
strain of C. difficile. Rates were higher for whites than for
other racial/ethnic groups.
Clostridium difficile is an anaerobic, gram-positive bacillus that can
cause considerable disease, including diarrhea, colitis, and septicemia, resulting in
death (1). C. difficile–associated disease (CDAD) primarily
affects persons >65 years. Risk factors include residence
in hospitals and long-term care facilities and the use of antimicrobial medications
(1–3). Incidence of CDAD has been increasing, and severe cases are becoming more
common (4,5). These changes in the incidence and severity of CDAD may be associated with the
emergence of a more virulent strain of C. difficile bacteria (5,6). Death rates associated with C. difficile were reported to be
increasing from 1999 to 2002 in the United States and from 2001 to 2005 in England and
Wales (7,8). However, no trend analysis was conducted to evaluate the rate of increase. We
incorporated mortality data for the United States through the year 2004 to conduct trend
analyses of CDAD-related deaths and to examine demographic characteristics and
coexisting conditions reported in deaths from C. difficile infection.
The Study
CDAD-related deaths were identified by using multiple cause-of-death
data from national mortality records for 1999–2004.
CDAD-related deaths were defined as all deaths for which the
underlying cause of death or any of the contributing causes of death included the
International Classification of Diseases, 10th revision (ICD-10) code A04.7
(enterocolitis due to C. difficile). Information about the size and
demographic breakdown of the US population for each year during 1999–2004
was obtained from censal and intercensal year estimates with bridged race data
(9,10). Age-adjusted mortality rates were calculated by using the age distribution
of the 2000 US population as a standard (11). The US population was divided into 5 racial/ethnic categories: white,
Hispanic, Asian/Pacific Islander, black, and American Indian/Alaska Native.
During 1999–2004, CDAD was reported as a cause of death for 20,642
persons. CDAD was reported as the underlying cause for 12,264 (59%) of these deaths.
A total of 3,256 deaths were reported related to all other intestinal infectious
diseases combined (ICD-10 codes A00 to A09, excluding A047) over the same period.
The median age of death for CDAD patients was 82 years. Age-adjusted mortality rates
from CDAD were slightly higher for men than for women (Table) and were higher for whites than for any other
racial/ethnic group. Most CDAD-related deaths occurred in hospitals (n = 16,557,
80%); 1,634 (8%) occurred in long-term care facilities, and 2,027 (10%) occurred at
home.
Demographic characteristics of patients with Clostridium
difficile–related deaths, United States,
1999–2004
Demographic group
C.
difficile–related deaths, no. (%)
Age-adjusted mortality
rate/million population
Sex
Female
12,468 (60)
11.8
Male
8,174 (40)
12.7
Race/ethnicity
White
18,534 (90)
12.9
Hispanic
602 (3)
7.2
Black
1.304 (6)
9.3
Asian/Pacific Islander
139 (1)
3.5
American Indian/Alaska
Native
63 (<1)
7.9
Age group, y
<1
17 (<1)
0.7*
1–4
11 (<1)
0.1*
5–14
12 (<1)
0.1*
15–24
24 (<1)
0.1*
25–34
62 (<1)
0.3*
35–44
171 (1)
0.6*
45–54
464 (2)
2.0*
55–64
1,159 (6)
7.6*
65–74
3,238 (16)
29.3*
75–84
7,859 (38)
104.0*
>85
7,623 (37)
287.1*
Total
20,642
12.2
*This statistic is not age-adjusted because it only pertains to 1 age
group.
Common coexisting conditions for CDAD-related deaths included septicemia (n = 7,654,
37%), renal failure (n = 4,786, 23%), pneumonia (n = 3,430, 17%), urinary tract
infection (n = 1,496, 7%), and anemia (n = 785, 4%). HIV was reported for 81
CDAD-related deaths (<1%). However, among the 697 deaths reported in persons
25–54 years of age, HIV was reported for 72 (10%).
The overall rate of C. difficile–related deaths during
the study period was 12.2 deaths per million population. Mortality rates related to
CDAD increased during the study period (Figure), rising from 5.7 deaths per million population in 1999 to 23.7
deaths per million population in 2004. Poisson regression estimates showed mortality
rates increased by 35% per year (coefficient = 0.30, standard error = 0.004, 95%
confidence interval = 0.29–0.31) during the study period.
Yearly Clostridium difficile–related mortality
rates per million population, United States, 1999–2004.
Conclusions
Due to the inclusion of CDAD-related deaths when CDAD was not reported as the
underlying cause of death, reported death rates in this study were higher than those
published in an earlier analysis of CDAD-related deaths in the United States (7). C. difficile is a cause of a substantial and increasing
proportion of deaths in the United States and may be underrecognized as a cause of
death. Little attention has been paid to C. difficile prevention;
media and public health awareness efforts have focused largely on the prevention of
disease from other intestinal pathogens such as Escherichia coli or
Salmonella. However, the incidence of deaths from C.
difficile is greater than the extent of deaths from all other
intestinal infectious diseases combined. C.
difficile–related mortality rates were higher for whites than
for other racial/ethnic groups. Racial/ethnic differences in insurance status and
access to care (12) may render elderly whites more likely to receive treatment with
antimicrobial drugs that put them at risk for C. difficile
infection. However, genetic or other factors may also be involved, and further
research is needed to determine the causes of racial/ethnic differences in
C. difficile–related deaths.
Previous research showed increases in CDAD-related mortality rates in the United
States until 2002 (7,8). This analysis estimates the rate of increase at 35% per year, and shows
that mortality rates continued to increase at least until 2004. Increases in
incidence and deaths from CDAD may be associated with the emergence of a new and
more virulent strain of C. difficile (5). The emergence of virulent strains of C. difficile makes
continued assessment of mortality statistics important.
Infection with C. difficile is associated with recent use of
antimicrobial medications and with residence in hospitals. Most CDAD cases are
acquired in healthcare settings (1), and as many as 90% of cases may be associated with antimicrobial drug use
(2,3). High C. difficile death rates call attention to the
importance of proper infection control practices in hospitals and long-term care
facilities and the judicious use of antimicrobial medications. Further research is
needed to explore current questions concerning which antimicrobial medications, if
any, will lead to CDAD (13,14).
Infections such as septicemia, pneumonia, and urinary tract infections were commonly
reported in conjunction with C. difficile–related
deaths. For some of these patients, the administration of antimicrobial medications
to treat infections from other pathogens may have paved the way for infection with
C. difficile. However, other risk factors are known, so that in
many cases the careful use of antimicrobial agents may not be enough to prevent
C. difficile infection. HIV infection was only reported in a
small fraction of CDAD–related deaths. However,
immunosuppression and the use of prophylactic antimicrobial drugs in persons with
AIDS may increase the risk for CDAD (15), and the effects of HIV should not be overlooked. In persons
25–54 years of age, in whom HIV infection is most common, HIV infection
was reported in approximately one tenth of CDAD-related deaths.
Thus, HIV can considerably increase C. difficile death rates for
demographic groups in which HIV prevalence is high.
Death certificate data may underrepresent the extent of CDAD-related deaths. This
analysis was limited to deaths in which ICD-10 code A047 (enterocolitis due to
C. difficile) was mentioned and may have failed to capture
CDAD-related deaths in which colitis was not present. In addition, death certificate
data may be affected by reporting error. Supplemental information such as
decedents’ medical histories was unavailable. No data were available
regarding which strains of C. difficile were responsible for
reported CDAD–related deaths.
C. difficile is an underrecognized cause of severe illness and
death. This analysis underscores the importance of CDAD as a public health problem
and the increasing incidence of CDAD-related deaths in the United States.
Suggested citation for this article: Redelings MD, Sorvillo F,
Mascola L. Increase in Clostridium difficile–related
mortality rates, United States, 1999–2004. Emerg Infect Dis [serial
on the Internet]. 2007 Sep [date cited]. Available from
http://www.cdc.gov/eid/content/13/9/1417.htm
Mr Redelings is an epidemiology analyst with the Los Angeles County Department of
Public Health. He previously served as a humanitarian worker in Sudan. His current
research interests include the epidemiology of gastrointestinal infections and the
prevention of disease in refugee situations.
ReferencesKellyCP, PothoulakisC, LaMontTJClostridium difficile colitis.N Engl J Med1994;330:257–6210.1056/NEJM1994012733004068043060BignardiGERisk factors for Clostridium
difficile infection.J Hosp Infect1998;40:1–1510.1016/S0195-6701(98)90019-69777516BarbutF, PetitJCEpidemiology of Clostridium
difficile–associated infections.Clin Microbiol Infect2001;7:405–1010.1046/j.1198-743x.2001.00289.x11591202McDonaldLC, BanerjeeS, JerniganDB Increasing incidence of Clostridium
difficile–associated disease in US acute care hospitals,
1993–2001. Presented at the 14th Annual Scientific Meeting of the
Society for Healthcare Epidemiology in America; Apr 17–20,
2004; Philadelphia. Abstract 67.PepinJ, ValiquettteL, AlaryMEClostridium
difficile–associated diarrhea in a region of Quebec from
1991 to 2003: a changing pattern of disease severity.CMAJ2004;171:466–7210.1503/cmaj.104110415337727KuijperEJ, CoignardB, TullPESCMID Study Group for Clostridium
difficile; EU Member States; and European Centre for Disease
Prevention and Control (ECDC). Emergence of Clostridium
difficile–associated disease in North America and
Europe.Clin Microbiol Infect2006;12(Suppl
6):2–1810.1111/j.1469-0691.2006.01580.x16965399WysowskiDKIncrease in deaths related to enterocolitis due
to Clostridium difficile in the United States,
1999–2002.Public Health Rep2006;121:361–216827436Deaths involving MRSA and Clostridium
difficile continue to rise. Health Stat Q. 2007; Press
release: 1–3.National Center for Health
Statistics Bridged-race intercensal estimates of the July 1,
1990–July 1, 1999, United States resident population by
county, single-year of age, sex, race, and Hispanic origin. [cited 2007 Mar 30].
Available from http://www.cdc.gov/nchs/about/major/dvs/popbridge/datadoc.htm#inter1National Center for Health
Statistics Estimates of the July 1, 2000–July 1,
2004, United States resident population from the vintage 2003
postcensal series by year, county, age, sex, race, and Hispanic origin. [cited
2007 Mar 30]. Available from http://www.cdc.gov/nchs/about/major/dvs/popbridge/datadoc.htm#inter1AndersonRN, RosenbergHMAge standardization of death rates:
implementation of the year 2000 standard.Natl Vital Stat Rep1998;47:1–16,
20AdamsPF, BarnesPMSummary health statistics for the U.S.
population: National Health Interview Survey, 2004.Vital Health Stat 102006;229:1–10416918080DhallaIA, MamdaniMM, SimorAE, KoppA, RohonPA, JuurlinkDNAre broad-spectrum fluoroquinolones more likely
to cause Clostridium difficile–associated
disease?Antimicrob Agents Chemother2006;50:3216–910.1128/AAC.00592-0616940135GaynesR, RimlandD, KillumE, LoweryHK, JohnsonTM, KillgoreG, Outbreak of Clostridium difficile infection in a
long-term care facility; association with gatifloxacin use.Clin Infect Dis2004;38:640–510.1086/38155114986246SanchezTH, BrooksJT, SullivanPS, JuhaszM, MintzE, SworkinMS, Bacterial diarrhea in persons with HIV infection, United States,
1992–2002.Clin Infect Dis2005;41:1621–710.1086/49802716267735